Cargando…

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

BACKGROUND/AIMS: In this study, we tested whether mutations in the methylation pathway genes ten-eleven-translocation 2 (TET2) and DNA methyltransferase gene 3A (DNMT3A) improve the responses of patients with myelodysplastic syndrome (MDS) to decitabine. METHODS: We retrospectively sequenced the TET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hyun Ae, Jung, Chul Won, Jang, Jun Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969079/ https://www.ncbi.nlm.nih.gov/pubmed/33086776 http://dx.doi.org/10.3904/kjim.2019.385

Ejemplares similares

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
por: Kim, Seungyoun, et al.
Publicado: (2021)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
por: Zhang, Zheng, et al.
Publicado: (2021)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
por: Yi, Jun Ho, et al.
Publicado: (2018)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation
por: Boy, Maxime, et al.
Publicado: (2023)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes
por: Yang, Yanli, et al.
Publicado: (2020)

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome
por: Wu, Lingyun, et al.
Publicado: (2016)

Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation
por: Zeng, Wen, et al.
Publicado: (2017)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

P739: INCREASED FOXO1 EXPRESSION IS ASSOCIATED WITH BETTER PROGNOSIS IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING DECITABINE THERAPY
por: Zhang, Zheng, et al.
Publicado: (2023)

Whole-Genome DNA Methylation Sequencing Reveals Epigenetic Changes in Myelodysplastic Syndromes
por: Zhou, Jing-dong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_63jrocfkjr2kd81sbn5gklle74